[Report: microbiological stool testing in adults and children with diarrhea: relevance and measures to promote judicious use]
Viel É, Fortin A
Record ID 32018001752
French
Original Title:
Avis: Analyses microbiologiques des selles en cas de diarrhée chez l’adulte et l’enfant : pertinence et pistes d’action pour une utilisation judicieuse
Authors' objectives:
Diarrhea is the distinctive clinical presentation of gastroenteritis. It is often infectious in
origin and is self-resolving. However, certain clinical presentations require an
investigation to determine the etiology of the diarrhea and to permit adequate
management of the person at risk for complications. The investigation consists primarily
of microbiological stool testing which can detect bacterial, parasitic or viral
enteropathogens responsible for infectious gastroenteritis.
Due to some concerns about requests for microbiological stool tests that are not clinically
warranted (particularly those for parasites), the Ministère de la Santé et des Services
sociaux (MSSS) asked the Institut national d’excellence en santé et en services sociaux
(INESSS) to produce clinical decision support tools to promote judicious use of these
laboratory analyses, especially by front-line health professionals. The objective of this
work was to make recommendations regarding the situations justifying a request for
microbiological stool testing, in order to guide and harmonize the practice across the
province. This work and the consultative process involved also led to the development of
a set of recommendations aimed at improving the organization and continuum of
services.
Authors' results and conclusions:
RESULTS: Based on the information gathered, it appears that the criteria for requesting bacterial or
viral stool testing are relatively well understood by clinicians, while those for parasite
testing are challenging for some professionals, especially those working on the front
lines. The decision-making process leading to requests for microbiological stool analysis
has therefore been clarified, with criteria based on duration, severity, specific clinical
situations, risk of exposure to enteropathogens, and the possibility that the diarrhea is not
of infectious etiology, for both the adult and pediatric populations.
Infectious diarrhea (especially if suspected of being viral) usually requires no
investigation. The precautionary principle must nonetheless be applied, unless the
affected person presents with rectal bleeding, fever or severe abdominal pain, or an
immunodeficiency, especially in the presence of impaired cellular immunity, or when the
diarrhea has persisted for at least 7 to 10 days. In such cases, bacterial stool analysis is
necessary. In the case of rectal bleeding associated with recent travel to an endemic
country, or when diarrhea persists for more than 14 days with no sign of improvement,
parasitic stool testing is also warranted. In addition, it is clinically appropriate to order
parasite microbiological testing when the results of the bacterial analysis are negative,
especially if the diarrhea has lasted for at least 10 to 14 days. Beyond such steps, a
microbiology/infectious disease physician, a pediatrician or a gastroenterologist is usually
consulted. These test requests require the collection of a single stool specimen to test for
bacteria and parasites, unless the parasite of interest is only detectable by microscopy, in
which case two or three specimens are needed. Certain clinical information appears to be essential for guiding the laboratory in the use of appropriate techniques for bacterial, and especially parasitic, testing. In particular,
laboratories must be informed of the presence of rectal bleeding or mucus in the stool, of
the risk of exposure (travel, immigration or international adoption, contact with farm or
sick animals) and of the immune status of the symptomatic person. However, most
requisition forms do not permit quick input of this clinical information, and clinicians are
not required to include it, which can contribute to inappropriate use of microbiological
stool tests. The province’s laboratory information system (LIS), whose implementation will
start in late 2021, has the potential to improve the input fields for these tests in the data
entry software and on the requisition forms. The heterogeneity of the request forms both
within and between clusters (that is, groups of medical laboratories) poses a challenge
for judicious use of these tests, given the varying and sometimes incomplete clinical
information provided to the laboratories, depending on the region of Québec concerned.
Harmonizing the microbiological stool test requisition process across the province could
therefore facilitate tasks for the requesting physicians and laboratories. Also, incomplete
information and errors in transcription and data input by the personnel sending the
request electronically to the laboratory can lead to its cancellation by the laboratory,
raising an additional issue. Lastly, when the request is processed and the analyses are
completed, the laboratories generate a report containing a list of the microorganisms
found in the stool, which is sent to the requesting clinician. The patient’s condition may
then require the involvement of a microbiology/infectious disease physician, pediatrician
or gastroenterologist to assess the need to initiate treatment. In such cases, the
laboratory report could include information on the pathogenicity or non-pathogenicity of
the microorganisms found, especially regarding parasites, to better guide the clinician.
A stepwise approach to investigating suspected infectious diarrhea can have a positive
impact on reducing the number of clinically unwarranted analysis requests. Such a
diagnostic approach should therefore be encouraged. However, other issues also
contribute to requests for microbiological stool tests that are not clinically relevant, thus
increasing laboratory workload, slowing down the production of results and consequently
delaying the diagnosis of gastroenteritis or another clinical condition. Indeed, most
Québec laboratories identify enteropathogens via conventional techniques (e.g., stool
culture and microscopy), which results in turnaround times of up to 4 to 5 days for
bacteria and several weeks for parasites. Requesting clinicians might thus be inclined to
order multiple microbiological stool tests simultaneously to expedite patient management
whereas the requests should be processed in order of priority based on the clinical
presentation.
The nucleic acid amplification test detects enteropathogens and yields results quickly and
with greater sensitivity, reducing result turnaround times, especially for tests for parasites.
According to Centralab data, most bacterial testing is done with stool cultures, which
generates costs of over $1 million annually, even though they detect only five types of
bacteria, whereas, at a similar cost per test unit, NAAT detects seven strains of bacteria
as well as Shiga toxins. However, Centralab’s supraregional designation limits its
implementation to the four clusters that have laboratories in the province’s teaching
hospitals. For parasite testing, microscopy (for which producing results is laborious and
time-consuming) is the main technique used in Québec and has a lower overall per-unit
cost than NAAT. However, NAAT detects the four parasites most commonly found in
stool quickly and simultaneously. The use of this parasite test, which has been
implemented in six clusters, depends however on the prioritization of needs by the
laboratories, since its inclusion in the Répertoire does not oblige it to be used. Therefore,
the benefit of NAAT being used for enteric bacteria and parasite detection by those
laboratories that are not already doing so rests on the fact that it could support clinicians
in the judicious use of microbiological stool tests by speeding up result turnaround times.
However, it does not replace bacterial culture in notifiable disease (maladie à declaration
obligatoire, MADO) situations, antibiotic susceptibility testing or parasite analyses, which
are not part of the current parasite NAAT kit and analysis 45098 registered in the
Répertoire.
Based on the assumptions used for the budget impact analysis of the bacterial and
parasitic NAATs currently listed in the Répertoire, and on the sensitivity analyses
performed to assess the impact of varying the weighted value (± 20%) and the number of
tests (± 20%), the estimates for the regional deployment of bacterial and parasitic NAATs
and the judicious use of these tests could vary from $1.8M in savings to $2M in additional
costs. The expected savings would be even greater if the weighted value associated with
the tests or the number of tests were lowered.
CONCLUSIONS: While not a substitute for clinical judgment, the recommendations made and the decision
support tool developed on their basis should promote the judicious use of microbiological
stool tests, reduce workload at microbiology laboratories, and improve result turnaround
times. The overall emphasis of the proposed recommendations is on clarifying the key
elements to be taken into account when making a clinical evaluation, on the choice of
microbiological stool tests according to the clinical situation, and on the situations where
consulting a microbiology/infectious disease physician, pediatrician or gastroenterologist
should be considered. The potential resulting practice changes will depend, however, on
the dissemination of the tool, the adherence to these changes, and the uptake of the
related recommendations by the health professionals concerned. Monitoring the volume
of tests over the next few years should allow assessment of the impact of INESSS’s
recommendations on the use of microbiological stool tests with regard to the various
parameters discussed in this report.
Authors' recommendations:
The recommendations are featured in the decision support tool primarily intended for
front-line clinicians. This work also identified areas where health professional knowledge needs be
strengthened. Thus, INESSS has made two recommendations for the overall
improvement of knowledge and expertise pertaining to microbiological stool tests. To improve the diagnostic continuum and promote judicious use of microbiological stool
testing, to shorten turnaround times, and to reduce the workload of those laboratories
that are still using time-consuming and laborious techniques on a first-line basis, INESSS
has made two recommendations for the deployment of NAAT for bacterial and parasitic
stool testing in all of the province’s cluster laboratories, since it is the fastest and most
sensitive molecular method. In addition, in order to harmonize practice regarding the number of specimens to be
submitted when ordering microbiological stool testing, to reduce the number of cancelled
test requests and to limit the performance of unwarranted tests, INESSS has made five
recommendations aimed at standardizing the practice at the regional, or even provincial,
level, and at improving the transmission of relevant clinical information to laboratories. Lastly, in order to reduce the number of questions from requesting clinicians about
microbiological stool test results, INESSS has made a recommendation that information
be added to the laboratory test reports transmitted to requesters.
Authors' methods:
This work was based on a review of the best available scientific data evaluated by the
authors of clinical practice guides (CPGs) and clinical guidelines (CGs), supplemented by
experiential knowledge gathered from various stakeholders through an informal
deliberative process. The systematic search for guides and guidelines was conducted in
several bibliographic databases and covered the period from January 2007 to December
2019. A search was also conducted in September 2017 and again in December 2020 by
consulting the websites of health technology assessment agencies and organizations,
government agencies, and professional associations and bodies associated with the topic
of interest. In August 2021, a final verification of these organizations was carried out to
check if they had published any new documents that were appropriate for inclusion.
Documents were selected according to predefined exclusion and inclusion criteria, and
the retained items were assessed for methodological quality using validated tools. These
steps were carried out independently by two professional scientists. The relevant
information and recommendations were then extracted by one professional scientist and
validated by the other. The results were presented in tables and summarized in the form
of a narrative synthesis. A professional scientist performed a quantitative synthesis and a
budget impact analysis of the costs associated with judicious use of the bacterial and
parasitic nucleic acid amplification tests (NAATs) currently listed in the Répertoire
québécois et système de mesure des procédures de biologie médicale (the Répertoire),
for the fiscal years 2018 to 2020. The perspectives of clinicians on current practice and
contextual issues, considering the information from the retained publications, were
gathered from the advisory committee members representing various specialties and
areas of expertise, the external reviewers and the members of both the monitoring
committee and the standing scientific committee on laboratory tests. Following
knowledge triangulation, preliminary proposals regarding clinical information critical for
decision-making and clinical recommendations on situations warranting microbiological
stool testing were made and then shared as a first iteration with the advisory committee
members. Two additional iterations were required before approval of formulations by a
majority of the committee members. During these discussions, the members were also
invited to give feedback on the applicability, acceptability and potential impact of the
clinical recommendations. Consideration of the contextual issues, particularly the barriers
to judicious use of such testing beyond the clinical aspects identified during the
consultations, led to formulation of recommendations on implementation, intended for the
Ministère de la Santé et des Services sociaux (the ministry), health-care institutions and
laboratories. These recommendations were shared with professional orders, federations
and associations to gauge their acceptability and applicability in each setting concerned.
The recommendations on implementation were developed and discussed with the
members of the advisory and monitoring committees.
Details
Project Status:
Completed
Year Published:
2021
URL for published report:
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/analyses-microbiologiques-des-selles-en-cas-de-diarrhee-chez-ladulte-et-lenfant-pertinence-et-pistes-daction-pour-une-utilisation-judicieuse.html
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Canada
Province:
Quebec
MeSH Terms
- Diarrhea
- Diagnostic Tests, Routine
- Clinical Laboratory Services
- Adult
- Child
- Feces
- Clostridium Infections
- Medical Overuse
Contact
Organisation Name:
Institut national d'excellence en sante et en services sociaux
Contact Address:
L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name:
demande@inesss.qc.ca
Contact Email:
demande@inesss.qc.ca
Copyright:
Gouvernement du Québec
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.